HAPLOTYPE ANALYSIS OF CYP11B2

被引:171
|
作者
WHITE, PC
SLUTSKER, L
机构
[1] Division of Pediatric Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX
关键词
D O I
10.3109/07435809509030459
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymorphisms affecting the synthesis of aldosterone or its regulation may have effects on blood pressure. For example, an autosomal dominant form of human hypertension, glucocorticoid suppressible hyperaldosteronism, is caused by recombination between the genes for aldosterone synthase (CYP11B2) and steroid 11 beta-hydroxylase (CYP11B1), creating a chimeric gene in which the CYP11B1 promoter and CYP11B2-specific coding sequences are juxtaposed. Thus, aldosterone synthesis is improperly regulated. We have begun an analysis of the human CYP11B2 and CYP11B1 genes to see if frequent polymorphisms exist and if they are correlated with differences in blood pressure. We have found frequent polymorphisms in CYP11B2. One in the promoter influences binding of the transcriptional regulatory protein, SF-1. Another is a gene conversion in intron 2 so that most of the intron has a sequence corresponding to CYP11B1. These polymorphisms are in linkage disequilibrium, defining 3 haplotypes. Blacks and whites differ significantly (p < 0.001) in the frequency with which these haplotypes occur. Further studies are required to determine if the observed differences between blacks and whites in blood pressure and in aldosterone levels can be explained in part by these allelic differences in CYP11B2 or by other polymorphisms in linkage disequilibrium on these haplotypes.
引用
收藏
页码:437 / 442
页数:6
相关论文
共 50 条
  • [41] Application of CYP11B2 immunohistochemistry in the histopathological diagnosis of primary aldosteronism
    杨溢
    China Medical Abstracts (Internal Medicine), 2020, 37 (01) : 26 - 27
  • [42] Histopathological Diagnosis of Primary Aldosteronism Using CYP11B2 Immunohistochemistry
    Nanba, Kazutaka
    Tsuiki, Mika
    Sawai, Kuniko
    Mukai, Kuniaki
    Nishimoto, Koshiro
    Usui, Takeshi
    Tagami, Tetsuya
    Okuno, Hiroshi
    Yamamoto, Tetsuro
    Shimatsu, Akira
    Katabami, Takuyuki
    Okumura, Ataru
    Kawa, Gen
    Tanabe, Akiyo
    Naruse, Mitsuhide
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (04): : 1567 - 1574
  • [43] Discovery of orally available aldosterone synthase (CYP11B2) inhibitors
    Papillon, Julien P. N.
    Adams, Christopher M.
    Hu, Qi-Ying
    Ksander, Gary M.
    Carvalho, Jose
    Lou, Changgang
    Singh, Alok K.
    Zhang, Chun
    Gangl, Eric
    Maniara, Wieslawa M.
    Amaral, Adam
    Logman, Michael
    Smith, Sherri
    Jeng, Arco Y.
    Rigel, Dean F.
    Beil, Michael E.
    Fu, Fumin
    Hu, Chii-Whei
    LaSala, Daniel
    Rajan, Srinivasan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [44] Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2)
    Martin, Rainer E.
    Lehmann, Johannes
    Alzieu, Thibaut
    Lenz, Mario
    Corrales, Marjorie A. Carnero
    Aebi, Johannes D.
    Marki, Hans Peter
    Kuhn, Bernd
    Amrein, Kurt
    Mayweg, Alexander V.
    Britton, Robert
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2016, 14 (25) : 5922 - 5927
  • [45] Regulation of human CYP11B1 and CYP11B2 promoters by transposable elements and conserved cis elements
    Cheng, Li-Chuan
    Pai, Tun-Wen
    Li, Lih-Ann
    STEROIDS, 2012, 77 (1-2) : 100 - 109
  • [46] Clinical significance of CYP11B2 immunostaining in unilateral primary aldosteronism
    Viukari, Marianna
    Leijon, Helena
    Vesterinen, Tiina
    Soederlund, Sanni
    Haemaelaeinen, Paeivi
    Yliaska, Iina
    Rautiainen, Paeivi
    Rintamaeki, Reeta
    Soinio, Minna
    Poersti, Ilkka
    Nevalainen, Pasi, I
    Matikainen, Niina
    ENDOCRINE CONNECTIONS, 2024, 13 (02)
  • [47] Variants of the CYP11B2 gene predict response to therapy with candesartan
    Ortlepp, JR
    Hanrath, P
    Mevissen, V
    Kiel, G
    Borggrefe, M
    Hoffmann, R
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 445 (1-2) : 151 - 152
  • [48] Differences in HRV parameters are observed in relation to CYP11B2 polymophisms
    Orlowska-Baranowska, E
    Gora, J
    Gaciong, Z
    Michalek, P
    Stepinska, J
    EUROPEAN HEART JOURNAL, 2004, 25 : 591 - 591
  • [49] Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors
    Papillon, Julien P. N.
    Adams, Christopher M.
    Hu, Qi-Ying
    Lou, Changgang
    Singh, Alok K.
    Zhang, Chun
    Carvalho, Jose
    Rajan, Srinivan
    Amaral, Adam
    Beil, Michael E.
    Fu, Fumin
    Gangl, Eric
    Hu, Chii-Whei
    Jeng, Arco Y.
    LaSala, Daniel
    Liang, Guiqing
    Logman, Michael
    Maniara, Wieslawa M.
    Rigel, Dean F.
    Smith, Sherri A.
    Ksander, Gary M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (11) : 4749 - 4770
  • [50] CYP11B2 expression in HSCs and its effect on hepatic fibrogenesis
    Xu Li Ying Meng Xi Shan Yang Ping Sheng Wu Shu Mei Li Wen Yan Lai The PLA Institute for Digestive Diseases
    World Journal of Gastroenterology, 2000, 6 (06) : 885 - 887